搜索
Location:
Homepage
/
/
/
Analysis of Influencing Factors in the Development of Veterinary Drug Industry from 2012 to 2013

Analysis of Influencing Factors in the Development of Veterinary Drug Industry from 2012 to 2013

  • Categories: Industry news
  • Author:
  • Origin:
  • Time of issue:2019-05-06
  • Views: 30

(Summary description) The overall R&D level is low. Compared with developed countries, the overall R&D level of veterinary drug enterprises in my country is relatively low, and the technological industrialization capability needs to be improved, which restricts the development of my country's veterinary drug industry to a certain extent.

Analysis of Influencing Factors in the Development of Veterinary Drug Industry from 2012 to 2013

(Summary description) The overall R&D level is low. Compared with developed countries, the overall R&D level of veterinary drug enterprises in my country is relatively low, and the technological industrialization capability needs to be improved, which restricts the development of my country's veterinary drug industry to a certain extent.

  • Categories: Industry news
  • Author:
  • Origin:
  • Time of issue:2019-05-06
  • Views: 30
Information
Disadvantages:
The overall R&D level is low. Compared with developed countries, the overall R&D level of veterinary drug enterprises in my country is relatively low, and the technological industrialization capability needs to be improved, which restricts the development of my country's veterinary drug industry to a certain extent. In 2010, there were 1,685 veterinary drug manufacturers in my country that passed the GMP acceptance certification for veterinary drugs, but about 80% of them were powder production lines, and their R&D strength was generally weak, and there was no corresponding R&D team to support them. The difference is huge. The annual R&D investment of foreign brand veterinary drug companies accounts for about 12% to 15% of the overall sales revenue, while the average investment of Chinese veterinary drug companies is less than 5%, resulting in the backward R&D capabilities and weak technological innovation capabilities of my country's veterinary drug industry. The technical sources of veterinary drugs are mainly universities, research institutes and other research institutions as well as foreign technology introduction, and the capabilities of enterprises in engineering and technology industrialization are relatively weak.
The homogeneity of market products is more serious. The technical level of enterprises in the industry is generally low, resulting in insignificant differentiation of veterinary drug products, especially in the chemical drug market, where homogeneity of low-end products is very common. The competition among manufacturers is mainly based on price wars, which has compressed the profit margins of the veterinary drug industry to a certain extent. Eliminating the phenomenon of product homogeneity can only be achieved through technology and product innovation, but currently there are few leading manufacturers in the market with outstanding advantages in technology and R&D strength.
Favorable factors:
National industrial policy support. The veterinary drug industry is the foundation for the development of animal husbandry and is related to the national economy and people's livelihood and the safety of animal-derived food. The state attaches great importance to the healthy and stable development of the veterinary drug industry, and encourages the research and development and industrialization of animal vaccines and efficient and safe new veterinary drugs. As biological preparations, animal vaccines belong to a strategic emerging industry that the state encourages and encourages development. The state has continuously introduced relevant incentive policies and measures, providing policy support for the rapid growth of veterinary drug companies with core competitive advantages.
Huge market space.
my country is a big country in animal husbandry, and the huge breeding scale of animal husbandry provides sufficient market guarantee for the veterinary drug industry. At the same time, the increase in the income of the aquaculture industry has contributed more than 30% to the increase in the income of farmers' families, becoming one of the main sources of farmers' income. "The State Council's Opinions on Stabilizing Agricultural Development and Promoting Farmers' Income Increase" (Guo Fa [2009] No. 25) clearly pointed out that it is necessary to promote the stable development of animal husbandry, which includes three aspects: increasing production input, strengthening market regulation and strengthening epidemic prevention and control. specific comments were made. The healthy development of animal husbandry is an urgent need for farmers to increase income and agricultural efficiency, which will further create a huge market space for the veterinary drug industry.
Continuous transformation of the breeding structure
The development of my country's pig and poultry breeding industry towards intensive and large-scale development is a current development trend and an inevitable development direction in the future. The larger the scale of the breeding enterprise, the greater the risk it will take, the stronger the corresponding social responsibility will be, and the more attention will be paid to the health protection of the animals it breeds. Large-scale breeding enterprises are highly dependent on veterinary drug products, and generally choose high-end veterinary drug products that are safe and efficient. Although the proportion of veterinary drug expenditure in the total cost of breeding is small, the effect of drug use determines the economic benefits of breeding enterprises to a large extent. Disease prevention and control is a very important part of the breeding process. If the prevention and control effect is not good, the breeding risk will increase, which will cause serious consequences. loser. Therefore, the higher the degree of intensification and scale of animal husbandry, the stricter the state's supervision of food safety, and the higher the quality requirements of customers for veterinary drug products. .
Gradual improvement of regulatory system and epidemic prevention system
Since the implementation of the new "Veterinary Drug Administration Regulations" in 2004, the state has successively issued a series of laws and regulations to regulate the development of the veterinary drug industry. At present, my country has established a management standard for the production and operation of veterinary drug industry based on veterinary drug GMP and GSP standards, as well as a veterinary drug product approval number issuance and supervision and management system, and has improved the registration, management and patent protection measures for new veterinary drugs. Laws and regulations such as the Animal Epidemic Prevention Law of the People's Republic of China and the Food Safety Law of the People's Republic of China have strengthened the supervision and enforcement mechanism of the veterinary drug industry. The state implements compulsory immunization against animal diseases that seriously endanger the production of aquaculture and human health, and has established a complete set of compulsory immunization plans. The division of responsibilities, organization and implementation, vaccine supervision, financial support, supervision and inspection of institutions are clearly stipulated. With the gradual improvement of the animal disease prevention and control system, the demand for public health safety and the continuous changes in animal epidemics, the state will gradually expand the scope of compulsory immunization, which will provide veterinary drug manufacturers with technological innovation advantages and rapid market response capabilities. Huge market opportunity.
Keyword:

Scan the QR code to read on your phone

天元药业

Tianyuan Pharmaceutical

Add: No. 34, Changsheng Street, Luquan District, Shijiazhuang City, Hebei Province  Tel:0086-311-83980006/83980378  Fax:0086-311-83980378  E-mail:ty@tianyuanyaoye.com.cn

COPYRIGHT © Hebei Tianyuan Pharmaceutical Co., Ltd.